The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study | Zendy

Tiffany R. Lago | Zendy; Michael Brownstein | Zendy; Emily Page | Zendy; Emily Beydler | Zendy; Adrienne Manbeck | Zendy; Alexis Beale | Zendy; Camille Roberts | Zendy; Nicholas L. Balderston | Zendy; Eve Damiano | Zendy; Suzanne L. Pineles | Zendy; Neal G. Simon | Zendy; Monique Ernst | Zendy; Christian Grillon | Zendy

Open Access

The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study

Author(s) -

Tiffany R. Lago,

Michael Brownstein,

Emily Page,

Emily Beydler,

Adrienne Manbeck,

Alexis Beale,

Camille Roberts,

Nicholas L. Balderston,

Eve Damiano,

Suzanne L. Pineles,

Neal G. Simon,

Monique Ernst,

Christian Grillon

Publication year - 2021

Publication title -

psychopharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.378

H-Index - 196

eISSN - 1432-2072

pISSN - 0033-3158

DOI - 10.1007/s00213-021-05861-4

Subject(s) - antagonist , psychology , vasopressin , anxiety , vasopressin receptor , neuroscience , neuropeptide , receptor antagonist , pharmacology , receptor , medicine , psychiatry

Arginine vasopressin (AVP) is a neuropeptide that modulates both physiological and emotional responses to threat. Until recently, drugs that target vasopressin receptors (V1a) in the human central nervous system were unavailable. The development of a novel V1a receptor antagonist, SRX246, permits the experimental validation of vasopressin's role in the regulation of anxiety and fear in humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research